(24/7 Market News) Elevation Oncology, Inc. (NASDAQ: ELEV) is trading at $4.12, 60 cents higher (+17.05%) in premarket, on 2,077,429 shares, compared to its 43,590 average daily volume.
The clinical stage biopharmaceutical company announced, this morning, that the U.S. Food and Drug Administration (FDA) granted seribantumab, Elevation Oncology’s tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions product, Fast Track designation.
Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology, stated, “There are currently no approved therapies that specifically target NRG1 fusions, and therefore, receipt of Fast Track designation in a tumor-agnostic setting is a significant step in addressing this unmet need.”
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
